Jane Perlmutter
Impact in
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
Papers in
-
- Breast Cancer Treatment Studies 46
- Cancer Genomics and Diagnostics 3
-
- Statistical Methods in Clinical Trials 12
- Co-authors
- W. Fraser Symmans (8 shared papers)Meredith M. Regan (3 shared papers)Lisa A. Carey (2 shared papers)Sunil R. Lakhani (2 shared papers)M. Elizabeth Hammond (2 shared papers)Giuseppe Viale (2 shared papers)Tracey Weisberg (2 shared papers)Antonio C. Wolff (2 shared papers)
- Journals
- Journal of Clinical Oncology (14 papers)Annals of Oncology (5 papers)JAMA Oncology (5 papers)Annals of Surgical Oncology (4 papers)Clinical Cancer Research (4 papers)
- Partner nations
- United StatesCanadaAustralia
In The Last Decade
Jane Perlmutter
80 papers receiving 12.7k citations
Jane Perlmutter's Hit Papers
Peers
Comparison fields: 5 of 128
- Cancer Research 6.6k
- Oncology 3.2k
- Pathology and Forensic Medicine 825
- Radiology, Nuclear Medicine and Imaging 763
- Pulmonary and Respiratory Medicine 1.1k
Countries citing papers authored by Jane Perlmutter
This map shows the geographic impact of Jane Perlmutter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Perlmutter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Perlmutter more than expected).
Fields of papers citing papers by Jane Perlmutter
This network shows the impact of papers produced by Jane Perlmutter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Perlmutter. The network helps show where Jane Perlmutter may publish in the future.
Co-authors
The 25 scholars most cited alongside Jane Perlmutter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 82 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer Hit paper breakdown → | 2010 | 3623 |
| 2 | Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update Hit paper breakdown → | 2020 | 1081 |
| 3 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version) Hit paper breakdown → | 2010 | 912 |
| 4 | 2010 | 816 | |
| 5 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer Hit paper breakdown → | 2020 | 584 |
| 6 | Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer Hit paper breakdown → | 2016 | 475 |
| 7 | Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline Hit paper breakdown → | 2018 | 461 |
| 8 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer | 2010 | 380 |
| 9 | 2019 | 319 | |
| 10 | 2016 | 303 | |
| 11 | 2014 | 287 | |
| 12 | 2020 | 276 | |
| 13 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial Hit paper breakdown → | 2021 | 264 |
| 14 | Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer Hit paper breakdown → | 2022 | 261 |
| 15 | Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies Hit paper breakdown → | 2022 | 243 |
| 16 | 2014 | 212 | |
| 17 | 2020 | 176 | |
| 18 | 2021 | 158 | |
| 19 | 2018 | 150 | |
| 20 | 2014 | 149 |
About Jane Perlmutter
Jane Perlmutter is a scholar working on Cancer Research, Statistics and Probability, Oncology, Public Health, Environmental and Occupational Health and General Health Professions, having authored 82 papers that have together received 13k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (46 papers), Statistical Methods in Clinical Trials (12 papers), Ethics in Clinical Research (9 papers), Cancer survivorship and care (5 papers), HER2/EGFR in Cancer Research (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer Genomics and Diagnostics (3 papers) and Brain Metastases and Treatment (3 papers). The work is most often cited by research in Cancer Research (6.6k citations), Oncology (3.2k citations), Pathology and Forensic Medicine (825 citations), Radiology, Nuclear Medicine and Imaging (763 citations) and Pulmonary and Respiratory Medicine (1.1k citations). Jane Perlmutter has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include W. Fraser Symmans, Meredith M. Regan, Lisa A. Carey, Sunil R. Lakhani, M. Elizabeth Hammond, Giuseppe Viale, Tracey Weisberg, Antonio C. Wolff, Daniel F. Hayes and Kimberly H. Allison. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, JAMA Oncology, Annals of Surgical Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.